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Abstract
Hamsters are widely used to generate monoclonal antibodies against mouse, rat, and human antigens, but sequence and
structural information for hamster immunoglobulins is sparse. To our knowledge, only three hamster IgG sequences have
been published, all of which use kappa light chains, and no three-dimensional structure of a hamster antibody has been
reported. We generated antibody HL4E10 as a probe to identify novel costimulatory molecules on the surface of cd T cells
which lack the traditional ab T cell co-receptors CD4, CD8, and the costimulatory molecule CD28. HL4E10 binding to cd T
cell, surface-expressed, Junctional Adhesion Molecule-Like (JAML) protein leads to potent costimulation via activation of
MAP kinase pathways and cytokine production, resulting in cell proliferation. The cDNA sequence of HL4E10 is the first
example of a hamster lambda light chain and only the second known complete hamster heavy chain sequence. The crystal
structure of the HL4E10 Fab at 2.95 A ˚ resolution reveals a rigid combining site with pockets faceted by solvent-exposed
tyrosine residues, which are structurally optimized for JAML binding. The characterization of HL4E10 thus comprises a
valuable addition to the spartan database of hamster immunoglobulin genes and structures. As the HL4E10 antibody is
uniquely costimulatory for cd T cells, humanized versions thereof may be of clinical relevance in treating cd T cell
dysfunction-associated diseases, such as chronic non-healing wounds and cancer.
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Introduction
T cells of the cd lineage constitute an enigmatic cell population
which links adaptive and innate immunity [1]. Like ab T cells and
B cells, cd T cells undergo V(D)J rearrangements, but their cd T
cell receptor (TCR) diversity is created to a lesser extent by V gene
usage, than by skewing combination events in the CDR3 junctions
[2]. Interestingly, some cd T cell populations have highly restricted
V gene usage, preferred pairing of TCR chains, and entirely lack
junctional diversity, resulting in the expression of canonical TCRs
[3]. cd T cells have not been shown to recognize peptide/MHC
(major histocompatibility complex) complexes or utilize known
antigen processing and presentation pathways as for antigen
recognition by ab T cells. Instead, the specialized antigens and
antigen recognition requirements for cd T cells provide unique
immunoregulatory and immunoprotective functions [4,5,6,7]. cd
T cells comprise 1–10% of the T cell population in the body;
however, in selected tissues they are the majority or only T cell
population [8,9,10,11,12]. Functionally, cd T cells are believed to
perform immune system regulation and surveillance roles, such as
tumor cell recognition, maintenance of tissue homeostasis, and
tissue repair [1,9,10,12,13] and act as the first line of defense
against infection [7,14].
Dendritic epidermal cd T cells (DETC) are the only resident T
cell population in the skin [8,10]. DETC are CD4 and CD8
double negative and do not express the costimulatory molecule
CD28 [9,15]. In fact, the majority of cd T cell populations do not
express CD4, CD8, or CD28 [8,14,16] and the absence of these
molecules represents an important finding because co-receptors
and costimulatory receptors are essential for tuning ab T cell
responses. Several diseases are correlated to dysfunction of
costimulation: autoimmune diseases [17,18,19,20,21], fatal dilated
cardiomyopathy [22], lymphoproliferative disorders and multi-
organ tissue destruction [23,24], and common variable immuno-
deficiency [25].
We generated monoclonal hamster antibodies against proteins
expressed on epithelial cd T cells to identify novel costimulatory
molecules that compensate for the lack of traditional co-receptors.
Binding of one of those antibodies, HL4E10, to epithelial cd T cell
surface-expressed JAML (Junctional Adhesion Molecule-Like)
receptor leads to potent costimulation via phosphoinsositide-
3-kinase recruitment, activation of Akt and MAP kinase pathways,
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19828and cytokine production, ultimately resulting in epithelial cd T cell
proliferation [15,26,27].
Hamsters are widely used to generate monoclonal antibodies
because they are less evolutionary related to mouse and rat than
these are to each other. Therefore, hamsters can generate good
immune responses to mouse and rat antigens, but still yield stable
hybridomas after fusion with mouse myeloma cells [28]. However,
sequence information for hamster immunoglobulins (Igs) is sparse.
To date, only one partial hamster IgM heavy chain DNA sequence
[29] and three hamster IgG DNA sequences, that code only for
kappa light chains, have been deposited in Genbank: the Cricetulus
migratorius antibody clones 1F4/3A5-1/4A6 (1F4 light chain:
Genbank accession no. S80615, 3A5-1 heavy chain: S80616)
[30], 145.2c11 (light chain: U17870, heavy chain: U17871) [31],
and H28.710 (light chain: U17165, heavy chain: U17166) [32,33].
Here, we report the first crystal structure of a hamster IgG Fab
fragment and the complete cDNA sequence of the stimulatory
antibody HL4E10 which contains the first example of a hamster
lambda light chain.
Materials and Methods
N-terminal protein sequencing of the HL4E10 hamster IgG
Hybridoma secreting HL4E10 IgG monoclonal antibodies
(mAb) were produced by fusing mouse myeloma cells with spleen
cells from an Armenian hamster (Cricetulus migratorius) immunized
with dendritic epidermal T cells (DETC, cell line 7–17), as
described elsewhere [15].
N-terminal, amino-acid sequences were obtained from purified
HL4E10 IgG (see next section) by Edman degradation (University
of Texas Medical Branch, Galveston, USA) of the HL4E10 light
and heavy chains. The SDS-PAGE-separated, PVDF-membrane
blotted HL4E10 light chain yielded the sequence SYTLTNPPL.
The N-terminus of the HL4E10 heavy chain was blocked by
pyroglutamate which had to be enzymatically removed prior to
Edman degradation. Since the HL4E10 heavy chain was unstable
in the standard reducing conditions (i.e. 50 mM Na-phosphate
pH 7.0, 10 mM DTT, 1 mM EDTA, 40–75uC for the several
hours [34,35,36] required for Pfu pyroglutamate aminopeptidase
(PGAP) activity), we investigated different reducing agents and
conditions and found that 50–90% of the HL4E10 heavy chain
remains intact after incubation at 40uC for 10 h in the presence of
1–2 mM b-mercaptoethanol.
PGAP deblocking of the HL4E10 heavy chain was achieved as
follows: 10 mU lyophilized Pfu PGAP (Takara Bio Inc., Japan) was
reconstituted in 50 ml of 50 mM Na-phosphate, 5 mM EDTA,
2.5 mM b-mercaptoethanol, pH 7.0 and heat activated by
incubation at 55uC for 2 min (heat activation has shown to
increase activity of PGAP, Singleton M. Thesis, University of
Exeter, 1997). 10 ml of the PGAP solution (2 mU) was added to
10 mg HL4E10 IgG in 15 ml of 50 mM Na-phosphate, 1 mM
EDTA. 0.1% Tween 20 was the added to the reaction mix to
improve enzymatic cleavage [36]. After the reaction was incubated
for 6 h at 40uC, a second 10 ml aliquot of the reconstituted enzyme
(2 mU) was added and the incubation continued at 40uC for
another 4 h. After SDS-PAGE, the samples were blotted onto a
PVDF membrane and the band corresponding to the HL4E10
heavy chain was submitted for Edman degradation. N-terminal
sequencing (after the PGAP removal of the N-terminal Gln)
yielded VQLKESGPGL.
cDNA sequencing of the HL4E10 hamster IgG
Degenerate oligonucleotide primers for HL4E10 light and
heavy chains were designed from the N-terminal sequences (light
chain degenerate sense primer: 59TAYACNYTNACNCAR-
CCNCCNYT39; heavy chain degenerate sense primer: 59CARG-
TNCARYTNAARGARWSNGGNCCNGGNYTN39). RNA was
isolated from HL4E10 mAb-secreting hybridoma cells using
Trizol (Invitrogen). cDNA was synthesized from total RNA and
HL4E10 cDNA amplified by 39RACE PCR using an RLM-
RACE kit (Ambion) and the above gene-specific 59 primers. PCR
products were cloned into pCR 2.1-TOPO (Invitrogen) and
subjected to DNA sequencing using M13 forward and reverse
primers.
To obtain the sequence of the 59UTR, specific antisense
primers were designed based on the sequences obtained from the
39RACE PCR products. Primers were as follows; light chain
antisense: 59ATTGGGCTGTACCTAGGACAGT39 and heavy
chain antisense: 59TCATTTACCGGGCCTCTGGGACAGA39.
RNA was subjected to 59RACE PCR using an RLM-RACE kit
and the above gene-specific 39 primers. PCR products were cloned
and sequenced as described above. Additional gene-specific
primers were used to verify sequences such that each base was
verified at least twice using PCR products obtained from
independent primer sets. The complete cDNA sequences of the
HL4E10 light chain and HL4E10 heavy chain have been
deposited in Genbank (accession numbers HM369134 and
HM369133, respectively).
Sequence analysis and comparisons
For hierarchical clustering, signal peptides were predicted using
SignalP 3.0 [37,38] and removed from their Ig light and heavy
chain amino-acid sequences before alignment with MUSCLE
[39]. Distance matrices, where distance is measured as the number
of amino acid substitutions per site, were calculated in MEGA4
[40] using 13 heavy chain amino acid sequences and 22 light chain
amino acid sequences and applying the Poisson correction model
[41]. Hierarchical clustering of distances was performed with
MultiDendrograms v2.1.0 [42] and displayed using the same
program. Sequence identities were calculated using the Smith-
Waterman algorithm [43,44]. Identification of rare amino-acid
residues at particular positions and Chothia canonical class
assignments using auto-generated SDR templates [45] were
performed with AbCheck [46,47]. Analysis of variable region
homology of the HL4E10 cDNA sequence to known human,
mouse and rat germline V, D and J sequences was conducted
using IMGT/V-QUEST [48].
Preparation and purification of HL4E10 Fab
Hybridoma cells secreting HL4E10 hamster IgG were cultured
in DMEM complete medium (Gibco, Invitrogen) with the
following supplements: 20% FCS, 2 mM L-Glutamine, 25 mM
HEPES buffer, 1 mM Na-pyruvate, 100 mM non-essential amino
acids, 100 U penicillin, 100 mg streptomycin, and 1x vitamins
(Irvine Scientific). Three liters of supernatant (added 0.02%
NaN3) were adjusted to pH 8.0 with 300 ml 1.0 M Tris-Cl
pH 8.0 and the IgG was bound to a Protein A-Sepharose (GE
Healthcare, BioRad) column. After washing with 500 ml of
Protein A binding buffer (0.1 M Tris-HCl, 3.0 M NaCl, 0.01 M
Na-EDTA, pH 8.9), the IgG was eluted with Protein A elution
buffer (0.10 M acetic acid, 0.15 M NaCl, pH 3.0) and
immediately neutralized with 100 mM NaHCO3 pH 9.0. The
IgG was digested with 4% Pepsin in 1.0 M Na-acetate pH 5.5 in
the presence of 20 mM cysteine. The reaction was stopped after
3 hours by addition of 1/7th volume of 1.0 M Tris-Cl pH 10.
Undigested IgG and Fc fragments were removed by exploiting
their affinity for a Protein A column. The unliganded Fab was
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16/100 columns.
Crystallization and data collection
The HL4E10 hamster IgG Fab (7 mg/ml) was crystallized
from 10–12.5% PEG 4000, 0.1 M Na-acetate pH 4.6, 0.2 M
(NH4)2SO4 at 22uC by sitting drop vapor diffusion by
mixing 0.5 ml protein solution with 0.5 ml reservoir solution.
Crystals nucleated overnight and grew to their final size of
0.0660.0360.02 mm within a week. A complete data set to
2.95 A ˚ was collected at the Stanford Synchrotron Radiation
Lightsource beamline 11–1 (Palo Alto, USA) and was integrated
and scaled with HKL2000 [49].
Structure determination, refinement, and analysis
The structure of the HL4E10 Fab was determined by molecular
replacement (MR) to 2.95 A ˚ resolution in monoclinic space group
P21 (VM=2.4 A ˚ 3/Da for two molecules per ASU). Using the
FFAS03: Fold, Function and Assignment Server [50], the HL4E10
Fab light and heavy chain sequences were threaded onto the
coordinates of the light and heavy chains of Fabs with the highest
sequence identity to HL4E10: the HYB3 Fab light chain (1W72,
65% sequence identity) and the YTS 105.18 Fab heavy chain
(2ARJ, 74% sequence identity). Using the SCWRL server {JCSG,
Joint Center of Structural Genomics, La Jolla, USA (jcsg.org)}, an
all atom model, which retained original rotamers for the conserved
residues, was generated for the individual light and heavy chain.
The chains were then reassembled into the VL:VH and CL:CH1
regions of an Fab molecule and MR solutions were found using
PHASER [51].
The MR model was subjected to rigid body refinement and
restrained all atom refinement with simulated annealing using
CNS [52]. Further refinement was achieved by alternating cycles
of model building with COOT [53] and refinement with CNS and
REFMAC5 [54]. The final model was refined to Rcryst=22.7%
and Rfree=28.1% (Table 1) and consists of two HL4E10 Fabs
(Fab 1: chain L residues 1–211, chain H residues 1–228; Fab 2:
chain A residues 1–211, chain B residues 1–228) per asymmetric
unit. No solvent molecules were added to the model due to the
moderate resolution of the structure determination. The final
statistics are shown in Table 1. The quality of the structure was
evaluated with PROCHECK [55], WHATCHECK [46], and
MOLPROBITY [56]. Superimpositions of the Ca atoms of the
entire Fab molecules LH and AB were done with SSM;
superimpositions of all atoms of the individual light and heavy
chains with LSQ, as implemented in COOT. Coordinates and
structure factors have been deposited in the PDB Protein Data
Bank with accession number 3MJ8.
Structure prediction and modeling
Structure prediction and generation of automated models of
HL4E10 was done with PIGS [57]. First, the three independent
heavy chains and light chains that best matched the canonical
structures of HL4E10 were identified (HC: 1W72, 2G75, 1ADQ;
LC: 1A7P, 1GIG, 1DL7). Next, while keeping loops with similar
canonical structures (n.b. HL4E10 CDRL1 and CDRL3 did not
match to any canonical structures of the templates and remained
not defined), side chains were modeled by transferring conserved
residues and predicting the conformations of non-conserved side
chains with SCWRL3.0 [58] for each of the three HC and three
LC templates. The resulting HC and LC variable domain models
were then superimposed with the experimentally determined
HL4E10 structure using SSM [59].
Results and Discussion
A mild protocol to remove N-terminal pyroglutamate
from reduction-sensitive proteins
To yield N-terminal protein sequences for primer design and
determination of the cDNA sequence of the stimulatory hamster
antibody HL4E10, we developed an optimized protocol for
enzymatic removal of N-terminal pyroglutamate residues from
reduction-sensitive proteins. Glutamine cyclization to pyrogluta-
mate is frequently found in proteins (n.b. most immunoglobulins
contain glutamine at the amino terminus of their heavy chains)
and inhibits N-terminal sequencing by Edman degradation
[34,60]. Pyroglutamates can be enzymatically removed using
pyroglutamate aminopeptidase (PGAP); however, the target
protein has to be stable under reducing conditions to prevent
oxidation of the PGAP catalytic cysteine [35]. Therefore, cleavage
Table 1. Hamster HL4E10 Fab data collection and refinement
statistics.
HL4E10 Fab
Data collection
Space group P21
Cell dimensions
a, b, c (A ˚) 43.8, 148.8, 68.8
a, b, c (u) 90.0, 106.2, 90.0
Wavelength (A ˚) 0.97946
Resolution (A ˚) 30.00–2.95 (3.06–2.95)*
Rmerge (%) 10.5 (54.1)*
,I/sI. 7.7 (1.7)*
Completeness (%) 95.3 (96.1)*
Unique reflections 17,012
Redundancy 2.3
Refinement
Resolution (A ˚) 30.00–2.95
No. reflections work/test 16,120/863
Rwork/Rfree (%) 22.7/28.1
No. atoms
Light chain L 1575
Heavy chain H 1585
Light chain A 1575
Heavy chain B 1585
B-values (A ˚2)
Light chain L 53
Heavy chain H 54
Light chain A 56
Heavy chain B 56
R.m.s deviations
Bond lengths (A ˚)0 . 0 0 6
Bond angles (u) 0.96
Ramachandran stats
Favored/allowed/outliers (%) 95.2/4.7/0.1
#
*Highest resolution shell is shown in parenthesis.
#Residue Asp
L170 is the only residue in the disallowed region, but is located in
region closely resembling a c-turn.
doi:10.1371/journal.pone.0019828.t001
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which, as for HL4E10 IgG, can affect the integrity of proteins with
disulfide bonds [34]. We screened different concentrations of
reducing agents, and reaction temperatures and found that,
after an initial 2 min heat activation of PGAP at 55uC, 1 mM
b-mercaptoethanol in the reaction mix is sufficient for PGAP
activity. The HL4E10 IgG did not degrade under these conditions
and the pyroglutamate at the N-terminus of the heavy chain was
successfully removed during 10 h incubation at 40uC. Our
modified, milder protocol for enzymatic removal of pyroglutamate
residues using PGAP should be generally useful for N-terminal
sequencing of reduction-sensitive proteins with pyroglutamate-
blocked N-termini.
The hamster HL4E10 IgG sequence in comparison to
other IgGs
Using degenerate primers derived from N-terminal protein
sequences, we determined the complete cDNA sequence for the
hamster IgG HL4E10. The light chain cDNA comprises 699 base
pairs (Genbank accession no. HM369134) encoding a 19-residue
signal peptide and a 213 amino acid mature protein chain (Fig. 1).
The HL4E10 heavy chain (HM369133) comprises 1389 base pairs
encoding a 19-residue signal peptide and a 443-residue mature
protein chain (Fig. 2).
While phylogenetic analysis of HL4E10 relative to other
antibodies was precluded by the unavailability of its germline
sequence, the mature sequence was analyzed to infer its overall
homology to known rearranged antibodies and identify the most
likely germline V(D)J constituents. According to pairwise distance
measurements between immunoglobulin sequences, calculated as
the number of amino acid substitutions per site, the HL4E10
heavy chain is generally more homologous to rodent IgG heavy
chains than to human IgG heavy chains (Fig. 3A). Average
distance from HL4E10 heavy chain sequence to the rat subgroup
IIa sequences shown in the dendrogram is 0.35 and 0.36 to the
mouse IgG1 subgroup sequences, while average distances to the
human IgG1 and IgG2 clades are 0.45 and 0.51, respectively.
Mouse subgroup IIa/b seems to differ from both its rat and human
Figure 1. Amino-acid sequence alignment of the HL4E10 hamster IgG light chain with those of other hamster antibodies. The HL4E10
lambda light chain is aligned with H28.710 (Genbank accession no. U17165 [32]), 145.2c11 (U17870 [31]), and 1F4 (S80615 [30]). Identical residues are
in red and homologous exchanges are in green. Signal peptides are underlined, CDR loops are shaded: CDR L1 is in yellow, CDR L2 is in cyan, CDR L3
is in orange-red, and residues which are rarely observed in antibodies at particular locations are shaded gray. Kabat numbering is used throughout, as
well as the definition of CDRs.
doi:10.1371/journal.pone.0019828.g001
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19828Figure 2. Amino-acid sequence alignment of the HL4E10 hamster IgG heavy chain with those of other hamster antibodies. The
HL4E10 heavy chain is aligned with H28.710 (U17166 [33]), 145.2c11 (U17871 [31]), and 3A5-1 (S80616 [30]). Color coding and shading is used as in
Fig. 1, CDR H1 is in blue, CDR H2 in pink, CDR H3 in green, and the glycine-, proline-, cysteine-rich hinge region between VHCH1 and CH2CH3 is shaded
gray.
doi:10.1371/journal.pone.0019828.g002
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the HL4E10 sequence than other rodent sequences. The only
other known hamster heavy chain sequence contains 0.39
substitutions per site relative to HL4E10 heavy chain. To put
distance measurements into a more intuitive perspective, HL4E10
shares 73.2% sequence identity with the rat IgG2a heavy chain
(GenBank ID AAH88240), 73.4% with the mouse IgG1
(AAH57688), 61.3% with the human IgG2 (CAA75032) and
65.4% with the other known hamster heavy chain sequence
(U17166). When compared to germline VDJ regions of other
species, HL4E10 cDNA sequence shares the most homology with
rat IGHV2 region (89% identity), mouse IGHD5 region (100%)
and human IGHJ4 region (83%).
Interestingly, the HL4E10 light chain is marginally more
homologous to human lambda light chains than to rodent
lambda light chains (Fig. 3B). The average distance to human
lambda is 0.42, while rat lambda chains have on average 0.58
and mouse 0.64 substitutions per site, respectively. Correspond-
ingly, HL4E10 shares 64.5% sequence identity with a human
lambda sequence (GenBank ID AAH70353), 59.8% with a rat
(ABD65259) and 58.4% with a mouse lambda sequence
(AAA39434). Alignment to germline human, rat, and mouse
sequences showed that HL4E10 light chain is most homologous
to the human IGLV3 region and human IGLJ3 region. The
HL4E10 lambda light chain sequence is dissimilar to the three
known hamster kappa light chain IgG sequences (0.82
substitutions per site and only 40.3%, 40.7% and 40.3%
sequence identity with the framework residues of U17165,
U17870, and S80615, respectively), whereas three hamster
kappa light chain sequences show only 0.24 amino acid
substitutions per site on average and 79.1% framework residue
sequence identity with each other. Rat, mouse and human
kappa sequences are also dissimilar from the HL4E10 sequence,
further supporting the classification of the HL4E10 light chain as
of the lambda type.
The HL4E10 variable sequence exhibits five residues which are
rarely observed at certain positions in antibodies: Thr
L3 is present
in only 0.70% of antibodies, Val
L31 (0.80%), His
L61 (0.06%),
Lys
L77 (0.48%), and Gln
H84, which is located in FR3, has never
been observed before at that location in an antibody sequence. An
interesting feature of the HL4E10 heavy chain sequence is the
glycine-rich hinge region connecting CH1 and CH2 (Fig. 2), which
might contribute to the ready degradation of the HL4E10 heavy
chain into the VHCH1 and CH2CH3 fragments in the presence of
reducing agents without any added proteases (as discussed above).
The HL4E10 CDR sequences can be assigned to the following
Chothia canonical classes: CDR H1, class 1/10A; CDR H2, class
1/9A; CDR L1, similar to class 2/11A, but differs in residues Tyr
2
(Chothia allowed: Ile), Gly
25 (Ala), Asp
26 (Ser), Leu
28 (Asn, Ser,
Asp, Glu), Ser
29 (Ile, Val), Asp
51 (Ala, Thr, Gly, Val), Ala
71 (Tyr,
Phe), Ser
90 (His, Gln); CDR L2, class 1/7A; CDR L3, similar to
class 5/11A but with Gln
89 (instead of Chothia allowed: Ala) and
Ser
90 (Ala). Furthermore, the CDR H3 sequence features a high
percentage (50%) of aromatic residues with two tyrosines and two
phenylalanines out of 8 residues (Fig. 2).
The crystal structure of the HL4E10 Fab
The crystal structure of the hamster HL4E10 Fab resembles
that of a typical Fab [61]. The two HL4E10 Fab molecules (chains
LH and AB) in the asymmetric unit do not significantly differ from
each other in their overall structure or in the conformation of the
combining site (Fig. 4A,B). The Ca atoms of the two Fabs in the
asymmetric unit superimpose with an r.m.s.d. of 0.63 A ˚; all atoms
of the light chains L and A superimpose with an r.m.s.d. of 0.79 A ˚;
and all atoms of the heavy chains H and B with an r.m.s.d. of
0.63 A ˚. The elbow angles between the variable and constant
Figure 3. Hierarchical clustering of the HL4E10 protein sequence with known immunoglobulins. Distances were calculated between
protein sequences of (A) heavy chains and (B) light chains as the number of amino acid substitutions per site. Scale bar indicates distances. GenBank
accession numbers of sequences included in the analysis are indicated within branch labels. Hierarchical clustering was performed on distance
matrices generated from protein sequences with removed signal peptides.
doi:10.1371/journal.pone.0019828.g003
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respectively. Because of the structural similarity of the two Fabs
in the asymmetric unit, we will limit our discussion to the
structural properties of Fab LH.
The HL4E10 combining site is composed of a relatively flat
central area (formed by Val
L31, Thr
H98, Trp
L96, Ile
H50, His
H95,
and Phe
H96), surrounded by more protruding residues (Asp
H31,
Tyr
H32 of CDR H1; His
H53-Asp
H58 of CDR H2; Asp
L30, Tyr
L32
of CDR L1; Arg
L53 of CDR L2; and Trp
L91 and Ser
L95A of CDR
L3) (Fig. 5A,B). A number of aromatic residues, i.e. three tyrosines
(Tyr
L32, Tyr
H32, Tyr
H97), one phenylalanine (Phe
H96), two
tryptophans (Trp
L91, Trp
L96), and two histidines (His
H35, His
H95);
and two aliphatic residues (Val
L31, Ile
H50) render the center of the
HL4E10 combining site rather hydrophobic in nature (Fig. 5C).
The side chains of two residues, namely Tyr
L32 and Tyr
H97, rise
significantly above the central plain of the combining site (Fig. 5A),
but do not exhibit any significant differences when comparing both
HL4E10 molecules in the asymmetric unit (Fig. 4B), suggesting that
Figure 4. Crystal structure of the HL4E10 Fab. (A) Cartoon representation of the superimposition of the two HL4E10 Fab structures in the
asymmetric unit. The two HL4E10 Fabs (LH and AB) are shown in dark and light gray, respectively. The CDR loops are color coded as in Fig. 1&2: CDR
L1 yellow, CDR L2 cyan, CDR L3 orange, CDR H1 blue, CDR H2 pink, CDR H3 green. The Ca atoms of Fab LH and Fab AB superimpose with an r.m.s.d.
of 0.63 A ˚.( B) Superimposition of the combining sites of HL4E10 Fab LH (CDR loops colored) and Fab AB (CDR loops gray) (in a similar orientation to
Fig. 4C) reveals a rigid assembly without significant conformational differences. (C) Wall-eyed stereo representation of the molecular interactions
which rigidify the HL4E10 CDR loops and lock the side chains in conformations predefined for high affinity ligand binding. For example, hydrogen
bonds (black), CH-p interactions (grey), and hydrophobic stacking interactions occur at the interface of CDR L3 with CDRs H3, H2, and H1.
doi:10.1371/journal.pone.0019828.g004
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optimized for ligand binding. The rigid arrangement of the
HL4E10 CDR loops is maintained by an extensive network of
hydrophobic stacking and CH-p interactions [62,63], and is further
stabilized by H-bonds between different CDR loops, as well as
between CDR loops and framework residues (Fig 4C). For example,
in the CDR L3 loop, Trp
L91 engages in a CH-p interaction with
Trp
L96, which H-bonds withThr
H98, and is alsoinvolved ina CH-p
interaction with His
H35. The latter residue stacks against Phe
H100
and H-bonds with Trp
H47. In the CDR H3, 5 out of 6 consecutive
residues have large, aromatic side chains (His
H95, Phe
H96, Tyr
H97,
Tyr
H99, Phe
H100) and are tightly packed between the CDR H1, L1,
L2, and L3 loops, thus constricting any significant motion (Fig. 4B).
Taken together, the rather rigid HL4E10 combining site serves as a
structural framework to optimally position the CDR residues for
HL4E10-JAML interaction [27] prior to antigen binding.
Figure 5. Molecular surface representations of the HL4E10 combining site. (A) Side view of the combining site in a similar orientation to
Fig. 4B. The central region is formed by Val
L31, Trp
L96, Ile
H50, His
H95, Phe
H96, and Thr
H98 and surrounded by Asp
H31 and Tyr
H32 of CDR H1; His
H53-Asp
H58
of CDR H2; Asp
L30 and Tyr
L32 of CDR L1; Arg
L53 of CDR L2; and Trp
L91 and Ser
L95A of CDR L3. Tyr
L32 and Tyr
H97 rise significantly above the central plain
of the combining site and Tyr
L32, Glu
L50, Tyr
H97, and Thr
H98 form a pocket on the HL4E10 surface. (B) View of the ligand-binding site after a 60u
rotation of (A) around the horizontal axis. (C) The electrostatic potential was mapped onto the molecular surface in the same orientation as (B) and
contoured at 610 kT/eV (blue/red). The largely hydrophobic character (white) of the HL4E10 combining site is defined by six aromatic (Tyr
L32, Tyr
H32,
Tyr
H97, Phe
H96, Trp
L91, and Trp
L96) and two aliphatic (Val
L31 and Ile
H50) residues.
doi:10.1371/journal.pone.0019828.g005
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a hamster antibody, its experimental structure was compared to
computationally predicted structures generated from canonical
structure search (Fig. 6). The three top scoring computational heavy
chain variable domain models, 1W72, 2G75, and 1ADQ, superim-
pose with HL4E10 with r.m.s.d.’s of 0.67, 0.60, and 0.78 A ˚,
respectively. For the LCs, the three top scoring variable domain
models 1A7P, 1GIG, and 1DL7 superimpose with HL4E10 with
RMSDs of 0.83, 0.66, and 0.81 A ˚, respectively. As expected, the
largest deviations are seen for CDR H3 (r.m.s.d. ’s of 1.0, 0.77, 0.99
A ˚), as well as for CDR L1 (r.m.s.d. ’s of 0.80, 0.73, 0.81 A ˚) and CDR
L3 (r.m.s.d. ’s of 0.90, 0.94, 1.20 A ˚) whose canonical classes could not
be unambiguously assigned. Nevertheless, given that no structural
information has been previously available for hamster IgGs, the
computationally predicted structure models compare surprisingly
very well to the experimentally determined HL4E10 structure.
Conclusion
We have determined the complete cDNA sequence and the
three-dimensional structure of the Fab fragment of a hamster
antibody stimulatory for cd T cells. The primary structure of
HL4E10 is the first example of a hamster lambda light chain
sequence, and its heavy chain sequence is only the second known
complete hamster heavy chain sequence. Thus, the cDNA
sequence of HL4E10 significantly extends our limited knowledge
of hamster immunoglobulin sequences. The crystal structure of the
unliganded HL4E10 Fab reveals an essentially rigid combining site
which is already conformationally optimized for interaction with
its ligand JAML. The binding of HL4E10 to cd T cell-expressed
JAML induces potent costimulation and ultimately cell prolifer-
ation, suggesting that humanized HL4E10 derivatives, might be
useful therapeutic tools for treatment of cd T cell dysfunction-
associated diseases, such as chronic non-healing wounds or cancer.
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